The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

In this free webinar, gain insight into the principles of mRNA and LNP technology and their unique advantages for in vivo CAR T-cell development. Attendees will learn how mRNA synthesis, LNP ...

In recent years, messenger RNA (mRNA) vaccines have shown significant success in preventing viral and bacterial infections, ...

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of an advanced animal mRNA vaccine platform to accelerate the development ...

CAMBRIDGE, Mass., August 28, 2025 – Raina Biosciences Inc., (“Raina”), an mRNA technology and therapeutics company, today announced the publication of data from its generative AI platform in Science.

Moderna, Inc. (NASDAQ:MRNA) today announced that it had voluntarily withdrawn the pending Biologics License Application (BLA) seeking approval for its COVID-19 and Influenza combination vaccine for ...

Researchers at the Icahn School of Medicine at Mount Sinai say they have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a ...

YONGIN, South Korea, Sept. 22, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading South Korean pharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) ...

The "mRNA Therapeutics Contract Development & Manufacturing Organization - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for mRNA ...

– GEMORNA is world’s first generative AI platform purpose-built for mRNA design and optimization, demonstrating state-of-the-art performance across diverse mRNA therapeutic applications – – GEMORNA ...